Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...

Newborns have elevated levels of an Alzheimer's biomarker

What do the brains of newborns and patients with Alzheimer's disease have in common? Both...

Content from other channels on our network

Inverell upgrades 30-year-old aeration system

Agricultural waste to create sustainable textiles

Sustainable shipping not a priority for retailers: report

Cleanaway acquires Citywide Waste

Grid simulation software to unlock future grid capacity

Sparc Hydrogen receives $2.75m commercialisation grant

Green approach to increase wastewater recycling in regional towns

US company to receive $4.9m from ARENA for solar installation robot trial

ANSTO technology removes key radioactive contaminant in critical minerals

Global manufacturing PMI up, Australia down slightly

Olivo and Brunetti Oro: cool partnership for fine food

Suntory Oceania’s $3bn beverage business launched in Qld

Heat and Control showcases sustainable food processing solutions

Top 5 keys to successful refrigerated transport in the last mile

Haigh's CEO announces retirement